Press Releases 2023 2022 2021 2020 2019 all June 1, 2023 Dyne Therapeutics to Present at Jefferies Healthcare Conference May 25, 2023 Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-101 May 17, 2023 Dyne Therapeutics’ Preclinical Data Demonstrating FORCE™ Platform Delivery to CNS Featured in Oral Presentation at ASGCT Annual Meeting May 11, 2023 Dyne Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights May 3, 2023 Dyne Therapeutics to Present at BofA Securities 2023 Healthcare Conference May 2, 2023 Dyne Therapeutics to Present New Preclinical Data at ASGCT Annual Meeting Demonstrating FORCE™ Platform Delivery to CNS March 23, 2023 Dyne Therapeutics Receives FDA Orphan Drug and Rare Pediatric Designations for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy March 20, 2023 Dyne Therapeutics Announces Presentations on its DM1 and DMD Programs at the 2023 Muscular Dystrophy Association Clinical & Scientific Conference March 7, 2023 Dyne Therapeutics to Present at Upcoming Investor Conferences March 2, 2023 Dyne Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights January 3, 2023 Dyne Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference
